| pubmed-article:16828290 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0025611 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C0961954 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C1100939 | lld:lifeskim |
| pubmed-article:16828290 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:16828290 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16828290 | pubmed:dateCreated | 2006-8-22 | lld:pubmed |
| pubmed-article:16828290 | pubmed:abstractText | Our previous studies demonstrated that the psychostimulant methamphetamine (MA) and the human immunodeficiency virus-1 (HIV-1) protein Tat interacted to cause enhanced dopaminergic neurotoxicity. The present study examined whether tumor necrosis factor-alpha (TNF-alpha) mediates the interaction between Tat and MA. In Sprague-Dawley rats, injections of Tat caused a small but significant increase in striatal TNF-alpha level, whereas MA resulted in no change. The increase in TNF-alpha induced by Tat + MA was not significantly different from that induced by Tat alone. Temporal analysis of TNF-alpha levels revealed a 50-fold increase 4 h after Tat administration. In C57BL/6 mice, Tat + MA induced a 50% decline in striatal dopamine levels, which was significantly attenuated in mice lacking both receptors for TNF-alpha. TNF-alpha synthesis inhibitors significantly attenuated Tat + MA neurotoxicity in hippocampal neuronal culture. The results suggest that Tat-induced elevation of TNF-alpha may predispose the dopaminergic terminals to subsequent damage by MA. | lld:pubmed |
| pubmed-article:16828290 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16828290 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16828290 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16828290 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16828290 | pubmed:issn | 0969-9961 | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:TheodoreShaji... | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:CassWayne AWA | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:SteinerJoseph... | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:MaragosWillia... | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:NathAvindraA | lld:pubmed |
| pubmed-article:16828290 | pubmed:author | pubmed-author:YoungKristieK | lld:pubmed |
| pubmed-article:16828290 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16828290 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:16828290 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16828290 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16828290 | pubmed:pagination | 663-8 | lld:pubmed |
| pubmed-article:16828290 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:meshHeading | pubmed-meshheading:16828290... | lld:pubmed |
| pubmed-article:16828290 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16828290 | pubmed:articleTitle | Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. | lld:pubmed |
| pubmed-article:16828290 | pubmed:affiliation | Graduate Center for Toxicology, University of Kentucky, Lexington, KY 40536, USA. | lld:pubmed |
| pubmed-article:16828290 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16828290 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:21926 | entrezgene:pubmed | pubmed-article:16828290 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:16828290 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16828290 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16828290 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16828290 | lld:pubmed |
